Results 101 to 110 of about 281,573 (395)

Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior

Haematologica, 2010
Background The concept of “accelerated” chronic lymphocytic leukemia is frequently used by both pathologists and clinicians. However, neither histological criteria to define this form of chronic lymphocytic leukemia nor its clinical correlates and ...
Eva Giné, Antoni Martinez, Neus Villamor, Armando López-Guillermo, Mireia Camos, Daniel Martinez, Jordi Esteve, Xavier Calvo, Ana Muntañola, Pau Abrisqueta, Maria Rozman, Ciril Rozman, Francesc Bosch, Elias Campo, Emili Montserrat   +14 more
doaj   +1 more source

Risk Factors of White Blood Cell Progression Among Patients With Chronic Lymphocytic Leukemia at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia

Cancer Informatics, 2022
Background: Leukemia is a type of cancers that start in the bone marrow and produce a serious number of abnormal white blood cells. Bleeding and bruising problems, fatigue, fever, and an increased risk of infection are among symptoms of the disease.
Gedam Derbew Addisia, Awoke Seyoum Tegegne, Denekew Bitew Belay, Mitiku Wale Muluneh, Mahider Abere Kassaw   +4 more
doaj   +1 more source

Leukostasis in Chronic Lymphocytic Leukemia

American Journal of Case Reports, 2020
BACKGROUND Chronic lymphocytic leukemia (CLL) is a mature B cell lymphocytic neoplasm that has an indolent clinical course. Therefore, not all patients with CLL require treatment at the time of diagnosis. Hyperleukocytosis (white blood cell count, >100×10⁹/L) is present in a large proportion of patients with CLL. However, symptomatic hyperleukocytosis (
Navdeep Singh, Gurinder Sidhu, Lech Dabrowski, Sandeep Singh Lubana   +3 more
openaire   +3 more sources

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases

BMC Cancer, 2019
Background Chronic lymphocytic leukemia is a malignancy with good prognosis. However, the incidence of secondary tumors increases every year after the diagnosis of chronic lymphotcytic leukemia. One of the induced secondary tumors is prostate cancer. For
Yinjie Zhu, Yanqing Wang, Zhiyu Qian, Jiahua Pan, Qiang Liu, Baijun Dong, Wei Xue   +6 more
doaj   +1 more source

Questions and answers about leukemia [PDF]

Leukemia is cancer of the white blood cells. It develops in the bone marrow and spreads into the blood and to other organs. There are several types of leukemia. They are grouped in two ways: by how rapidly the disease develops (acute vs. chronic leukemia)

core  

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

New England Journal of Medicine, 2011
BACKGROUND The somatic genetic basis of chronic lymphocytic leukemia, a common and clinically heterogeneous leukemia occurring in adults, remains poorly understood.
Lili Wang, M. Lawrence, Youzhong Wan, P. Stojanov, C. Sougnez, K. Stevenson, L. Werner, A. Sivachenko, D. DeLuca, Li Zhang, Wandi Zhang, Alexander Vartanov, S. Fernandes, Natalie R. Goldstein, Eric G. Folco, K. Cibulskis, B. Tesar, Quinlan L. Sievers, Erica Shefler, S. Gabriel, N. Hacohen, R. Reed, M. Meyerson, T. Golub, E. Lander, D. Neuberg, Jennifer R. Brown, G. Getz, Catherine J. Wu   +28 more
semanticscholar   +1 more source

Alemtuzumab in Chronic Lymphocytic Leukemia

Current Oncology, 2007
Questions: (1) With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (CLL)? (2) What toxicities are associated with the use of alemtuzumab? (3) Which patients are more likely—or less likely—
Fraser, G., Smith, C.A., Imrie, K., Meyer, R.   +3 more
openaire   +3 more sources

Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy

Advanced Healthcare Materials, EarlyView.
The review summarizes the synthesis of mesoporous silica nanoparticles (MSNs) with modifiable surface properties, functionalization strategies, mechanism of therapeutic payload release, and current applications in gene therapy, focusing on their capabilities in the targeted delivery of therapeutic nucleic acids, CRISPR‐Cas systems, and other genetic ...
Tamanna Binte Huq, Punnya Anil Kumar Jeeja, Sudip Kumar Dam, Sabya Sachi Das, Juan L. Vivero‐Escoto   +4 more
wiley   +1 more source